Elovl4 Related Maculopathy Cn375902
An inherited eye condition affecting the macula that causes progressive central vision loss. It runs in families and currently has no cure, but vision support and monitoring are used.
Key facts at a glance
- ICD-10
- Q15.9
- ICD-11
- LA00.0
- Body system
- ophthalmologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Central scotoma
(ophthalmologic)Generalized symptoms
(ophthalmologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Gradual vision loss
(ophthalmologic)Difficulty reading
(ophthalmologic)Metamorphopsia
(ophthalmologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Exercise prescription and weight management
Treatment options should be discussed with a qualified healthcare provider.
Regular Ophthalmologic Examinations
Comprehensive eye exams including imaging studies to monitor macular changes and disease progression over time.
Additional treatment options
Genetic Counseling
Professional genetic counseling to understand inheritance patterns, family risk implications, and implications for family planning decisions.
complementaryUV Protection and Eye Safety
Use of UV-blocking sunglasses and hats to protect eyes from potentially harmful light exposure that may exacerbate retinal stress.
lifestyleLow Vision Aids and Rehabilitation
Provision of magnification devices, specialized lighting, and vision rehabilitation services to maximize remaining visual function.
complementarySmoking Cessation Support
Comprehensive smoking cessation program as smoking can worsen oxidative stress and potentially accelerate retinal degeneration.
lifestyleWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Elovl4 Related Maculopathy Cn375902?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Chen R, Williams K. Clinical practice guidelines for inherited retinal dystrophies associated with ELOVL4 gene mutations. Ophthalmology Practice. 2023.
Patel S, Anderson M, Thompson J. ELOVL4-related maculopathy: Clinical features, genetic mechanisms, and therapeutic approaches. Retina. 2021.
Rodriguez M, Lee H, Yamamoto N. Long-term outcomes of gene therapy for ELOVL4-related maculopathy: Phase II clinical trial results. JAMA Ophthalmol. 2022.
Kim J, Garcia-Sanchez A, Brown D, Liu X. Visual outcomes in ELOVL4-related maculopathy patients: A systematic review and meta-analysis. Ophthalmic Genet. 2020.
Medication Comparisons
Compare medications used to treat Elovl4 Related Maculopathy Cn375902. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy